Creative Medical Technology Holdings, Inc.

What they do

The company develops regenerative medicine therapies derived from adult and perinatal stem cell technologies, using scalable cGMP manufacturing. It operates three proprietary cell platforms — AlloStem, ImmCelz and iPScelz — across orthopedics, immunotherapy, endocrinology, urology and gynecology. It has two FDA-cleared clinical trials in progress: CELZ 201 DDT (ADAPT), Olastrocel for chronic lower back pain from degenerative disc disease, a randomized Phase 1/2 study with FDA Fast Track designation, and CELZ 201 (CREATE 1) for new onset Type 1 diabetes, in Phase 1/2.

Revenue drivers

• Product and other revenue — The company reports negligible top-line revenue: $6,000 for fiscal 2025, down from $11,000 in 2024 and $9,000 in 2023, and $0 in the quarters ended 2025-09-30, 2026-03-31 and 2026-06-30.
• CELZ 201 (Olastrocel) clinical program — Lead clinical asset for chronic lower back pain due to degenerative disc disease, in a randomized Phase 1/2 ADAPT trial with FDA Fast Track designation; no revenue reported from this program.
• CELZ 201 (CREATE 1) Type 1 diabetes program — Phase 1/2 trial for new onset Type 1 diabetes; development-stage, with no revenue reported.
• CELZ Biodefense Platform — An AI-driven data and discovery initiative evaluating regenerative countermeasures for conditions linked to toxic environmental exposures such as military burn pits; no revenue reported.

Recent performance

Revenue was $0 in the quarters ended 2026-06-30 and 2026-03-31, and $3,000 in the quarter ended 2025-12-31. Fiscal 2025 revenue was $6,000 versus $11,000 in 2024. Net loss was $6.0 million in 2025, compared with $5.5 million in 2024 and $5.3 million in 2023. Operating cash flow was negative $5.9 million in 2025. As of 2026-06-30, total assets were $9.4 million, total liabilities $698,595, and shareholder equity $8.7 million, substantially all in cash and equivalents.

Strategy

Management says it is advancing CELZ 201 (Olastrocel) toward Phase 3 development for chronic lower back pain associated with degenerative disc disease, while the same asset anchors additional platform programs. The company describes a lean, cross-functional team supported by strategic partners, including third-party manufacturers, and says it allocates capital toward programs with clearer paths to differentiation, regulatory advancement and commercial or partnering potential. It also states that it integrates AI into drug development to analyze biological and clinical datasets, prioritize targets and candidates, and support shorter development timelines. The three cell platforms are intended to broaden market opportunity while diversifying development risk.

Risks

• No meaningful revenue — Revenue has fallen to $6,000 in fiscal 2025 and $0 in the two most recent quarters, leaving the company dependent on external capital.
• Clinical and regulatory uncertainty — Both FDA-cleared programs, ADAPT and CREATE 1, remain in Phase 1/2, so approval and commercialization are unproven.
• Listing-rule exposure — The company reported a delisting notice or listing-rule failure event on 2025-04-11.
• Cash burn relative to resources — Operating cash flow was negative $5.9 million in 2025 against $8.7 million of cash and equivalents at 2026-06-30.

Outlook

Management states it is advancing its lead asset CELZ 201 (Olastrocel) toward Phase 3 development for chronic lower back pain associated with degenerative disc disease. It also cites the CELZ Biodefense Platform and continued AI integration into drug development as ongoing initiatives. The filings describe a strategy of prioritizing programs with clearer paths to regulatory and partnering potential, without providing specific revenue or earnings guidance.